MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
Trial met its primary endpoint with MM-120 demonstrating a statistically significant dose-dependent improvement in HAM-A scores four weeks after a single-dose
MM-120 100µg demonstrated a clinically and statistically significant HAM-A...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Anxiety | Clinical Trials | Generalized Anxiety Disorder (GAD) | Pharmaceuticals | Statistics